Faculty of Pharmacy, Assiut University , 71526 Assiut, Egypt.
ACS Appl Mater Interfaces. 2017 Sep 6;9(35):29562-29570. doi: 10.1021/acsami.7b09916. Epub 2017 Aug 24.
Primary and secondary bone cancers are major causes of pathological bone fractures which are usually treated through implant fixation and chemotherapy. However, both approaches face many limitations. On one hand, implants may suffer from poor osseointegration, and their rejection results in repeated surgery, patient's suffering, and extensive expenses. On the other hand, there are severe systemic adverse effects of toxic chemotherapeutics which are administrated systemically. In this paper, in order to address these two problems, we present a new type of localized drug-releasing titanium implants with enhanced implants' biointegration and drug release capabilities that could provide a high concentration of anticancer drugs locally to treat bone cancers. The implants are fabricated by 3D printing of Ti alloy followed by an anodization process featuring unique micro- (particles) and nanosurface (tubular arrays) topography. We successfully demonstrate their enhanced bone osseointegration and drug loading capabilities using two types of anticancer drugs, doxorubicin (DOX) and apoptosis-inducing ligand (Apo2L/TRAIL). In vitro study showed strong anticancer efficacy against cancer cells (MDA-MB-231-TXSA), confirming that these drug-releasing implants can be used for localized chemotherapy for treatment of primary and secondary bone cancers together with fracture support.
原发性和继发性骨癌是病理性骨折的主要原因，通常通过植入物固定和化疗来治疗。然而，这两种方法都面临着许多限制。一方面，植入物可能存在较差的骨整合，其排斥反应导致反复手术、患者痛苦和大量费用。另一方面，全身给予的有毒化疗药物有严重的全身不良反应。在本文中，为了解决这两个问题，我们提出了一种新型局部释药钛植入物，具有增强植入物的生物整合和药物释放能力，可局部提供高浓度的抗癌药物来治疗骨癌。植入物是通过 Ti 合金的 3D 打印和具有独特的微观（颗粒）和纳米表面（管状阵列）形貌的阳极氧化处理来制备的。我们使用两种抗癌药物，阿霉素（DOX）和凋亡诱导配体（Apo2L/TRAIL），成功地证明了它们增强的骨整合和药物负载能力。体外研究显示对癌细胞（MDA-MB-231-TXSA）具有很强的抗癌疗效，证实这些释药植入物可与骨折支撑一起用于原发性和继发性骨癌的局部化疗。
